Literature DB >> 28893644

High bone mass due to novel LRP5 and AMER1 mutations.

Alice Costantini1, Päivi Kekäläinen2, Riikka E Mäkitie3, Outi Mäkitie4.   

Abstract

WNT signaling is a key regulator of bone metabolism and its increased or decreased activity leads to skeletal disorders. Here we describe two patients with high bone mass (HBM) caused by novel mutations in two different WNT pathway components. The first patient is a 53-year-old male with HBM. He was diagnosed at adult age based on significantly increased bone mineral density (BMD). He has undergone several surgeries due to excessive bone in ear canals, bilateral jaw exostoses and mandibular tori. Radiographs show severe cortical thickening of cranial and long bones. Sanger sequencing identified a novel heterozygous mutation c.592A>T (p.N198Y) in LRP5 (Low-density lipoprotein receptor-related protein 5). The second patient, an adolescent female, was diagnosed with skeletal dysplasia in early childhood. She had macrocephaly (head circumference +6.0 SD), facial dysmorphism, delayed motor development, laryngomalasia and epilepsy. Radiographic findings were consistent with osteopathia striata with cranial sclerosis. A novel heterozygous frameshift mutation c.655del (p.E219Rfs*63) in AMER1 (APC Membrane Recruiting Protein 1) was identified. Although both mutations are predicted to lead to increased WNT signaling with a consequent increase in bone formation, the resulting phenotypes are different; cranial sclerosis versus macrocephaly, long bone cortical thickening versus vertical striations and discordant neurological development. This report underscores the diversity of genotypes and phenotypes of HBM and facilitates their differential diagnosis.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  AMER1; High bone mass; LRP5; Osteopathia striata; WNT signaling

Mesh:

Substances:

Year:  2017        PMID: 28893644     DOI: 10.1016/j.ejmg.2017.09.001

Source DB:  PubMed          Journal:  Eur J Med Genet        ISSN: 1769-7212            Impact factor:   2.708


  3 in total

1.  Sclerostin neutralization unleashes the osteoanabolic effects of Dkk1 inhibition.

Authors:  Phillip C Witcher; Sara E Miner; Daniel J Horan; Whitney A Bullock; Kyung-Eun Lim; Kyung Shin Kang; Alison L Adaniya; Ryan D Ross; Gabriela G Loots; Alexander G Robling
Journal:  JCI Insight       Date:  2018-06-07

2.  Lrp4 Mediates Bone Homeostasis and Mechanotransduction through Interaction with Sclerostin In Vivo.

Authors:  Whitney A Bullock; April M Hoggatt; Daniel J Horan; Andrew J Elmendorf; Amy Y Sato; Teresita Bellido; Gabriela G Loots; Fredrick M Pavalko; Alexander G Robling
Journal:  iScience       Date:  2019-09-18

Review 3.  The Genetic Architecture of High Bone Mass.

Authors:  Celia L Gregson; Emma L Duncan
Journal:  Front Endocrinol (Lausanne)       Date:  2020-10-29       Impact factor: 5.555

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.